Clinical Trial Finder

Inclusion Criteria:

• - Participant has completed the EOS or End of Treatment Visit of Study PVO-1A-301 or PVO-1A-202 (PVO-1A-202 Parts C and D correspond to Study PVO-1A-204 in France) and did not previously withdraw consent from any of the parent studies to be eligible for Study CLIN-60120-452.

• - Participant must be ≥14 years of age (aligned with the age of treated participants in the ongoing parent studies PVO-1A-301 and PVO-1A-202/PVO-1A-204) and qualify as 100% skeletally mature (if <18 years, based on assessments carried out at parent EOS Visit; if ≥18 years, automatically considered 100% skeletally mature) or have reached final adult height based on investigator's assessment, at the time the Study CLIN- 60120-452 informed consent is signed.

Exclusion Criteria:

• - History of allergy or hypersensitivity to retinoids, gelatin, lactose (note that lactose intolerance is not exclusionary) or palovarotene, or unresponsiveness to prior treatment with palovarotene.

• - Uncontrolled cardiovascular, hepatic, pulmonary, gastrointestinal, endocrine, metabolic, ophthalmologic, immunologic, psychiatric, or other significant disease.

• - Symptomatic vertebral fracture.

• - Intercurrent known or suspected non-healed fracture at any location; - Any other medical condition/clinically significant abnormalities that would expose the participant to undue risk or interfere with study assessments.

• - Amylase or lipase >2× above the upper limit of normal (ULN) or with a history of chronic pancreatitis.

• - Elevated aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5× ULN.

• - Fasting triglycerides >400 mg/dL with or without therapy.

• - Suicidal ideation (type 4 or 5) or any suicidal behaviour at the Inclusion Visit as defined by the Columbia-Suicide Severity Rating Scale (C-SSRS).

• - Current use of vitamin A or beta carotene, multivitamins containing vitamin A or beta carotene, or herbal preparations, fish oil, and unable or unwilling to discontinue use of these products during palovarotene treatment.

• - Exposure to synthetic oral retinoids other than palovarotene within 4 weeks of the Inclusion Visit.

• - Concurrent treatment with tetracycline or any tetracycline derivatives due to the potential increased risk of pseudotumor cerebri.

• - Use of concomitant medications that are strong inhibitors or inducers of cytochrome P450 (CYP450) 3A4 activity; or kinase inhibitors such as imatinib.

• - Palovarotene is reimbursed in the country where the study is being conducted.

• - Any reason that, in the opinion of the investigator, would lead to the inability of the participant and/or family to comply with the protocol.

Arms

Interventions